Form 4: MindMed CMO Sells Shares for Tax Obligations

Mind Medicine's Chief Medical Officer, Daniel Karlin, sold 5,600 common shares for $13.1469 each to cover tax obligations related to vested restricted stock units.

Summary

• Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc. (MNMD), reported a sale of common shares.
• The transaction involved the disposition of 5,600 common shares on December 26, 2025.
• The shares were sold at a weighted average price of $13.1469 per share, with individual sales ranging from $13.02 to $13.33.
• The sale was conducted to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units.
• This transaction was executed pursuant to sell-to-cover elections under a Rule 10b5-1 plan, which was adopted on June 14, 2022.
• Following this transaction, Daniel Karlin beneficially owns 425,025 common shares directly.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell-to-cover' to satisfy tax obligations on vested restricted stock units, executed under a pre-arranged 10b5-1 plan. This type of transaction is generally considered neutral and does not reflect a change in management's outlook or confidence in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction (Form 4) for a Chief Medical Officer, common across all industries, particularly when executives receive equity compensation that vests over time. The use of a Rule 10b5-1 plan indicates a pre-planned sale designed to comply with insider trading regulations, rather than a discretionary sale based on new information.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned transaction for tax purposes and does not signal a change in company fundamentals or management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell-to-cover' transaction by Mind Medicine's Chief Medical Officer, Daniel Karlin, to satisfy tax obligations on vested restricted stock units. The sale was executed under a pre-established Rule 10b5-1 plan, indicating it was not a discretionary sale based on new material information. Such transactions are common for executives receiving equity compensation and typically do not reflect a change in the company's fundamental outlook or the insider's long-term confidence. Therefore, this filing provides no new information that would warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Mind Medicine, MNMD, Form 4, Insider Transaction, Stock Sale, Daniel Karlin, Chief Medical Officer, Restricted Stock Units, 10b5-1 Plan, Tax Obligations